NKGen Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	0	0	0.08	0.43
Revenue Growth (YoY)	-	-	-81.92%	-
Cost of Revenue	0	0	0.02	0.03
Gross Profit	0	0	0.06	0.4
Selling, General & Admin	15.26	14.08	7.66	7.59
Research & Development	15.31	15.67	16.75	14.67
Other Operating Expenses	0	0	0	0.08
Operating Expenses	30.57	29.75	24.41	22.34
Operating Income	-30.57	-29.75	-24.35	-21.95
Interest Expense / Income	1.78	0.75	2.31	1.32
Other Expense / Income	47.66	52.46	0.1	-
Pretax Income	-80.01	-82.95	-26.75	-23.26
Income Tax	0.01	0.01	0.01	0.01
Net Income	-80.01	-82.95	-26.75	-23.27
Shares Outstanding (Basic)	22	15	6	14
Shares Outstanding (Diluted)	22	15	6	14
Shares Change	64.77%	142.70%	-55.39%	-
EPS (Basic)	-4.65	-5.38	-4.21	-1.63
EPS (Diluted)	-4.65	-5.38	-4.21	-1.63
Free Cash Flow	-21.07	-22	-22.72	-20.01
Free Cash Flow Per Share	-0.96	-1.43	-3.57	-1.40
Gross Margin	-	-	76.62%	92.96%
Operating Margin	-	-	-31618.18%	-5151.41%
Profit Margin	-	-	-34745.45%	-5461.27%
Free Cash Flow Margin	-	-	-29506.49%	-4696.48%
EBITDA	-76.74	-80.64	-22.79	-20.7
EBITDA Margin	-	-	-29598.70%	-4859.39%
Depreciation & Amortization	1.49	1.57	1.65	1.24
EBIT	-78.23	-82.2	-24.44	-21.95
EBIT Margin	-	-	-31741.56%	-5151.41%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).